Home » Stocks » OCX

OncoCyte Corporation (OCX)

Stock Price: $1.79 USD 0.06 (3.47%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 120.38M
Revenue (ttm) 714,000
Net Income (ttm) -31.58M
Shares Out 67.25M
EPS (ttm) -0.51
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $1.79
Previous Close $1.73
Change ($) 0.06
Change (%) 3.47%
Day's Open 1.73
Day's Range 1.73 - 1.80
Day's Volume 157,091
52-Week Range 1.15 - 3.51

More Stats

Market Cap 120.38M
Enterprise Value 118.18M
Earnings Date (est) Apr 5, 2021
Ex-Dividend Date n/a
Shares Outstanding 67.25M
Float n/a
EPS (basic) -0.52
EPS (diluted) -0.51
FCF / Share -0.40
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.41M
Short Ratio 1.42
Short % of Float n/a
Beta 2.26
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 168.60
PB Ratio 2.96
Revenue 714,000
Operating Income -33.95M
Net Income -31.58M
Free Cash Flow -27.10M
Net Cash 2.20M
Net Cash / Share 0.03
Gross Margin -59.50%
Operating Margin -4,754.34%
Profit Margin -4,422.50%
FCF Margin -3,795.10%
ROA -42.97%
ROE -98.72%
ROIC -155.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.20*
(134.64% upside)
Low
2.00
Current: $1.79
High
6.00
Target: 4.20
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue-------
Operating Income-22.24-15.20-18.85-11.14-8.72-4.97-3.50
Net Income-22.43-15.75-19.38-11.17-8.74-4.99-3.50
Shares Outstanding51.3037.8530.2026.5321.0118.2018.20
Earnings Per Share-0.44-0.42-0.64-0.42-0.42-0.27-0.19
Operating Cash Flow-19.72-11.65-13.39-7.52-4.23-1.16-0.71
Capital Expenditures-0.92-0.03-0.09-0.11-0.50-0.01-0.03
Free Cash Flow-20.63-11.68-13.48-7.63-4.73-1.17-0.74
Cash & Equivalents22.458.468.3612.4910.543.54-
Total Debt5.941.722.500.51---
Net Cash / Debt16.526.745.8611.9710.543.54-
Assets39.869.5210.2214.4512.735.24-
Liabilities9.026.105.814.592.316.32-
Book Value30.843.424.409.8610.42-1.07-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name OncoCyte Corporation
Country United States
Employees 33
CEO Ronald Asbury Andrews

Stock Information

Ticker Symbol OCX
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: OCX

Description

OncoCyte Corporation engages in the development and commercialization of proprietary laboratory-developed tests for the detection of cancer. The company offers DetermaRx, a molecular tests for early stage adenocarcinoma of the lung; and DetermaIO, a novel gene expression-based tests. It also develops DetermaDx, a non-invasive blood-based tests used to detect lung cancer. OncoCyte Corporation has a strategic collaboration with Guardian Research Network, Inc. to create a solution for pharma clients from patient recruitment to regulatory approvals. The company was founded in 2009 and is headquartered in Irvine, California.